Merck KgaA, Mammoth Biosciences Partner to Produce, Scale Up Covid-19 Test
29 Outubro 2020 - 1:55PM
Dow Jones News
By Olivia Bugault
Merck KGaA said Thursday that it is collaborating with
California-based Mammoth Biosciences for the development, scale-up
and commercial production of Covid-19 diagnostic tests in the
U.S.
The New SARS-CoV-2 test developed by Mammoth could enable
performing roughly 1,500 tests per 8-hour shift, the German
pharmaceutical and chemicals company said.
"This collaboration will allow us to help Mammoth with the
development and production of their new SARS-CoV-2 test, which,
once approved by the FDA, will increase testing capacity here in
the U.S. at the scale needed to combat this pandemic," the head of
Merck's applied solutions, Life Science, said.
Mammoth Biosciences is planning to submit its CRISPR-based tests
for FDA emergency use authorization later this year, it said.
Write to Olivia Bugault at olivia.bugault@wsj.com
(END) Dow Jones Newswires
October 29, 2020 12:40 ET (16:40 GMT)
Copyright (c) 2020 Dow Jones & Company, Inc.
Merck KGAA (TG:MRK)
Gráfico Histórico do Ativo
De Mar 2024 até Abr 2024
Merck KGAA (TG:MRK)
Gráfico Histórico do Ativo
De Abr 2023 até Abr 2024
